Showing results (1-10 of 208) with videos related to
Sort By:
Pageof 21
Biochemical Pharmacology|July 19, 1994
Polyunsaturated fatty acids reduce pyrogen-induced tissue factor expression in human monocytesA Lalé, J M HerbertJournal of Cardiovascular Pharmacology|June 15, 1999
Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonistA Bernat, P Hoffmann, P Savi, et al.Platelets|August 12, 2000
Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonistP Savi, A Bernat, A Lalé, et al.Thrombosis and Haemostasis|October 6, 1998
The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbitJ M Herbert, F Dol, A Bernat, et al.Thrombosis and Haemostasis|February 1, 1996
Echinomycin suppresses the pyrogenic effects of endotoxin and interleukin-1 beta in human endothelial cells and peripheral blood mononuclear cellsJ M Herbert, A Lalé, J M Pereillo, et al.FEBS Letters|August 16, 1993
IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytesJ M Herbert, P Savi, M C Laplace, et al.Biochemical Pharmacology|September 15, 1994
Malformin-A1 inhibits the binding of interleukin-1 beta (IL1 beta) and suppresses the expression of tissue factor in human endothelial cells and monocytesJ M Herbert, P Savi, A Lalé, et al.Journal of Medicinal Chemistry|October 28, 1997
New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agentA Badorc, M F Bordes, P de Cointet, et al.Thrombosis and Haemostasis|October 6, 1998
SR 121787, a new orally active fibrinogen receptor antagonistP Savi, A Badorc, A Lalé, et al.Thrombosis and Haemostasis|April 20, 2001
Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonistC N Berry, J Lorrain, S Lochot, et al.Pageof 21